Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

PBRM1 (Polybromo 1)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

OncoGuide™ NCC Oncopanel System

TheraSure™-CNI MONITOR Assay

OncoGuide™ NCC Oncopanel System

TheraSure™-CNI MONITOR Assay

›

PBRM1 mutation	Clear Cell Renal Cell Carcinoma	PBRM1 mutation	Clear Cell Renal Cell Carcinoma	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B	Immunotherapy Sensitive: B - Late Trials Immunotherapy Sensitive : B
PBRM1 underexpression	Renal Cell Carcinoma	PBRM1 underexpression	Renal Cell Carcinoma	sorafenib Resistant: C3 – Early Trials sorafenib Resistant : C3	sorafenib Resistant: C3 – Early Trials sorafenib Resistant : C3
PBRM1 overexpression	Renal Cell Carcinoma	PBRM1 overexpression	Renal Cell Carcinoma	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3	sorafenib Sensitive: C3 – Early Trials sorafenib Sensitive : C3
PBRM1 mutation	Bladder Cancer	PBRM1 mutation	Bladder Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
PBRM1 mutation	Bladder Cancer	PBRM1 mutation	Bladder Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PBRM1 mutation	Non Small Cell Lung Cancer	PBRM1 mutation	Non Small Cell Lung Cancer	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PBRM1 mutation + FGFR2 fusion	Cholangiocarcinoma	PBRM1 mutation + FGFR2 fusion	Cholangiocarcinoma	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3	futibatinib Sensitive: C3 – Early Trials futibatinib Sensitive : C3
PBRM1 mutation	Lung Adenocarcinoma	PBRM1 mutation	Lung Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PBRM1 mutation + MSI-L/dMMR	Lung Adenocarcinoma	PBRM1 mutation + MSI-L/dMMR	Lung Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PBRM1 mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma	PBRM1 mutation + TMB-L + MSI-L/dMMR	Lung Adenocarcinoma	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3	Immunotherapy Resistant: C3 – Early Trials Immunotherapy Resistant : C3
PBRM1 mutation	Renal Cell Carcinoma	PBRM1 mutation	Renal Cell Carcinoma	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3
PBRM1 deletion	Renal Cell Carcinoma	PBRM1 deletion	Renal Cell Carcinoma	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3